Phase II Study of Bevacizumab-containing Regimen in Patients With Metastatic Colorectal Cancer Who Failed to Cytotoxic Treatment
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms BATTLE
- 22 May 2019 Planned End Date changed from 1 Nov 2018 to 1 Dec 2019.
- 22 May 2019 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2019.
- 29 Aug 2014 New trial record